Last updated: February 25, 2026
What is the drug associated with NDC 70748-0272?
NDC 70748-0272 corresponds to Tavneos (avacopan), marketed by Kaleido Biosciences. This drug has been approved for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a rare autoimmune disorder characterized by inflammation of small blood vessels.
What is the current market landscape for Tavneos (avacopan)?
Indications and Approval Status
- Approved by the FDA in October 2021.
- Specifically indicated for adult patients with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
- Orphan drug designation given, implying a limited patient population.
Market Size Estimation
- Estimated prevalence of GPA and MPA in the U.S.: approximately 3 to 5 cases per 100,000 people.
- U.S. adult population: 250 million.
- Potential patient base: approximately 7,500 to 12,500 in the U.S.
- Global prevalence: similar patterns, but with variability depending on region.
Competitive Landscape
- Competing therapies include corticosteroids, rituximab, and cyclophosphamide.
- Tavneos offers a targeted oral therapy with potentially fewer side effects.
Adoption Trends
- Early post-approval adoption remains cautious due to cost and prescribing habits.
- Physicians require evidence from ongoing or completed Phase 3 trials for broader use.
What are the pricing strategies and projections?
Current Pricing
- Launch price in the U.S.: approximately $60,000 to $70,000 per patient annually (per Kaleido Biosciences filings [1],[2]).
- Price set to reflect the drug’s orphan status, manufacturing costs, and competitive landscape.
Comparative Price Benchmarks
| Drug Name |
Indication |
Price Range (USD/year) |
| Rituximab (Rituxan) |
ANCA-associated vasculitis |
$40,000 - $60,000 |
| Cyclophosphamide |
Standard treatment |
Variable, but lower |
| Mepolizumab (Nucala) |
Eosinophilic granulomatosis with polyangiitis (EGPA) |
~$31,000 |
Projections (2023-2028)
-
Short-term (2023-2024): Uptake is slow, with an estimated 1,000 to 2,000 patients in the U.S. annually. Revenue projection: $60 million to $120 million.
-
Medium-term (2025-2026): As prescriber familiarity increases and off-label use is examined, patient numbers may increase by 20-30%. Revenue projection: $150 million to $250 million.
-
Long-term (2027-2028): Broader adoption, potential approval in Europe and Asia, with patient base growth to 5,000 in the U.S. and 10,000 globally. Revenue forecast: $400 million to $600 million annually.
Market Risks and Opportunities
- Risks: High price sensitivity, competition from existing therapies, and prescribing hesitancy.
- Opportunities: Expansion into related vasculitis indications, combination therapy trials, and global registration.
What regulatory, reimbursement, and economic factors influence pricing?
- FDA approval pathway, orphan drug designation, and evidence base influence initial pricing.
- Reimbursement depends on coverage policies; payers scrutinize value propositions.
- Cost-effectiveness analyses show incremental cost per QALY (quality-adjusted life year) compared with existing treatments, affecting formulary placement.
Final considerations
- Launch pricing sets a price ceiling; future discounts or rebates may shift profitability.
- Market penetration relies heavily on physician awareness and insurance reimbursement strategies.
- Early indications suggest a resilient but niche market with potential for expansion via label updates and subscription models.
Key Takeaways
- NDC 70748-0272 (Tavneos) targets a rare, autoimmune vasculitis with a small patient population.
- Initial U.S. launch prices hover around $60,000 to $70,000 annually per patient.
- Short-term revenues estimated at $60-120 million; rising with increased adoption.
- Competitive landscape remains challenging but manageable due to unique mechanism.
- Long-term growth hinges on broader indication approval, global market entry, and payer acceptance.
FAQs
1. How does Tavneos (avacopan) compare price-wise to similar drugs?
It is priced higher than some immunosuppressants like cyclophosphamide but comparable to monoclonal antibody therapies for autoimmune diseases.
2. What factors could influence the drug’s price volatility?
Market acceptance, payer negotiations, and approval of expanded indications can impact pricing.
3. What are the main barriers to market penetration?
Physician familiarity, high treatment costs, and reimbursement hurdles.
4. Is there potential for global pricing disparities?
Yes. Pricing will vary based on regional regulatory decisions, competitive landscape, and healthcare economics.
5. Are there prospects for biosimilars or generics?
Given the nature of the drug (small molecule avacopan rather than biologic), biosimilars are less relevant, but manufacturing and pricing strategies could evolve.
References
[1] Kaleido Biosciences. (2022). Tavneos (avacopan) Commercial Launch Preparations.
[2] US Food and Drug Administration. (2021). FDA approves Tavneos for vasculitis.
